Story

Neurocrine Biosciences Stock Slides on Vykat XR Safety Concerns

ENTHMSVIIDZHZH-TWJAKOHI
Aug 12, 20262 min read
Neurocrine Biosciences Stock Slides on Vykat XR Safety Concerns
Text size
Background

Shares of Neurocrine Biosciences (NASDAQ: NBIX) declined sharply Tuesday after a group of patient advocacy organizations raised safety concerns regarding the company's drug, Vykat XR. The stock fell 3.1% to close at $156.94 in afternoon trading.

Patient Groups Flag Adverse Events

The sell-off was triggered by a joint statement from three advocacy groups for patients with Prader-Willi syndrome. The statement cited post-marketing surveillance data from the U.S. Food and Drug Administration's (FDA) adverse event monitoring system.

According to the groups, the system has recorded seven patient deaths and more than 100 serious adverse events since Vykat XR was approved. Reported complications include edema, respiratory issues, and cardiac problems. While the organizations did not assert a direct causal link between the drug and the fatalities or call for a market withdrawal, the disclosure was significant enough to spook investors.

Company Response and Market Context

Neurocrine Biosciences CEO Kyle Gano responded publicly, stating the company does not believe the deaths are related to Vykat XR. However, the statement failed to halt the stock's downward momentum.

Sample IUX Markets – In-articleAd

The decline was company-specific, bucking a positive trend in the broader market. The S&P 500 and Nasdaq both posted modest gains Tuesday, buoyed by an in-line July Consumer Price Index (CPI) report. NBIX's underperformance indicates the drop was driven entirely by internal factors rather than macroeconomic pressures.

Compounding Headwinds

The safety concerns surrounding Vykat XR add to existing investor anxiety over potential pricing policy changes that could impact Neurocrine's flagship product, INGREZZA, which treats tardive dyskinesia. This overhang has continued to weigh on market sentiment.

Even the release of positive clinical data for INGREZZA from its KINECT-PRO Phase 4 study was not enough to offset the negative news. Despite the company reporting a record quarterly revenue of over $950 million in Q2 2026, the stock is likely to face continued pressure until investors and regulators gain more clarity on the safety profile of Vykat XR.

Read next

More on Stocks
Back to latest news

LATEST